A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma

IF 2.3 3区医学 Q1 OTORHINOLARYNGOLOGY

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck Pub Date : 2024-07-29 DOI:10.1002/hed.27887

Christopher D. Goodman MD, Franco DeMonte MD, Theresa P. Nguyen BS, Adam S. Garden MD, Catherine He Wang PhD, Xin A. Wang PhD, Kevin Diao MD, PhD, Anna Lee MD, Jay Reddy MD, PhD, Amy Moreno MD, PhD, Michael Spiotto MD, PhD, Clifton D. Fuller MD, David Rosenthal MD, Renata Ferrarotto MD, Shaan M. Raza MD, Shirley Y. Su MBBS, Andrew Warner MSc, Ehab Hanna MD, Jack Phan MD, PhD

{"title":"A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma","authors":"Christopher D. Goodman MD, Franco DeMonte MD, Theresa P. Nguyen BS, Adam S. Garden MD, Catherine He Wang PhD, Xin A. Wang PhD, Kevin Diao MD, PhD, Anna Lee MD, Jay Reddy MD, PhD, Amy Moreno MD, PhD, Michael Spiotto MD, PhD, Clifton D. Fuller MD, David Rosenthal MD, Renata Ferrarotto MD, Shaan M. Raza MD, Shirley Y. Su MBBS, Andrew Warner MSc, Ehab Hanna MD, Jack Phan MD, PhD","doi":"10.1002/hed.27887","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Treatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51–96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.</p>\n </section>\n </div>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":"47 1","pages":"81-89"},"PeriodicalIF":2.3000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hed.27887","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Treatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population.

Methods

ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed.

Results

Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51–96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis.

Conclusion

In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.

查看原文本刊更多论文

立体定向放射治疗治疗硬膜复发嗅神经母细胞瘤的前瞻性队列研究。

背景：嗅神经母细胞瘤（ONB）硬脑膜复发的治疗尚未标准化。我们评估了立体定向体放射治疗（SBRT）在这一人群中的疗效：方法：纳入2013年至2022年间接受前瞻性登记治疗的硬脑膜复发嗅神经母细胞瘤患者。对肿瘤控制情况、生存率和患者报告的生活质量进行分析：对14名患者的32处硬膜病变进行了评估。硬脑膜复发时间为58.3个月。30个病灶（94%）接受了SBRT治疗，中位剂量为27 Gy，分三次进行。两名患者（32个病灶中的3个；9%）出现了场内放射学进展，五名患者（38%）出现了非连续硬脑膜进展。两年的局部控制率为85%（95% CI：51-96%）。无3级以上急性毒性反应，1例晚期3级脑放射性坏死：在这项迄今为止规模最大的SBRT再照射治疗ONB硬脑膜复发的研究中，局部控制率高且毒性小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 医学-耳鼻喉科学

CiteScore

7.00

自引率

6.90%

发文量

278

审稿时长

1.6 months

期刊介绍： Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.